Axsome Therapeutics has received a positive signal from the FDA for its migraine treatment, AXS-07, with the acceptance of its resubmitted New Drug Application (NDA). This news could potentially diversify Axsome’s product portfolio and fuel further growth, alongside its existing products for major depressive disorder and narcolepsy. The FDA’s decision on the approval is expected on January 31, 2025.
Victoria Azarenka battled through a migraine during her second-round match at the US Open, ultimately defeating Clara Burel 6-1, 6-4 to advance to the third round.
Avulux and Eyenavision have teamed up to introduce Chemistrie Avulux, a new on-demand eyeglass clip designed for individuals with migraine and light sensitivity. This innovative product combines Avulux’s clinically proven migraine lenses with Eyenavision’s Chemistrie lens layering system, offering a convenient solution for patients seeking relief from migraine triggers.
Individuals who utilize acid-reducing medications, such as proton pump inhibitors and H2 blockers, may exhibit an elevated risk of experiencing migraines and severe headaches, as per a study published in Neurology ® Clinical Practice. The study, which involved over 11,000 participants, revealed that individuals taking proton pump inhibitors were 70% more likely to experience migraines, while those using H2 blockers were 40% more likely, and antacid supplement users were 30% more likely. While the study does not establish a causal relationship, it does suggest an association between acid-reducing drugs and migraine occurrence. Given the widespread use of these medications, further research is warranted to explore this potential link.
Migraine is a disabling neurological disease, not simply a headache. It affects millions worldwide, causing significant disability and impacting daily life. The condition is associated with various neurological, sensory, and other symptoms, affecting the whole body. Understanding the complexities of migraine is crucial for effective diagnosis and treatment.
Migraine sufferers in the UK may soon have access to a new drug, Atogepant, to help prevent their debilitating headaches. Recommended by NICE, Atogepant is designed specifically to block the CGRP protein, believed to contribute to migraine development, and has shown promising results in clinical trials.
